布地奈德缓释胶囊(Kinpeygo)全网公布的2024年的最新价格

Introduction: Budesonide extended-release capsules (Kinpeygo) are the first approved therapy specifically for the treatment of IgAN, which can help patients avoid or delay the need for dialysis or kidney transplantation. Budesonide extended-release capsules are an oral extended-release capsule dosage form that combines delayed disintegration of the capsule with prolonged release of budesonide in the ileum. The goal of this therapy is to inhibit mucosal B cells in Peyer's lymph nodes, thereby inhibiting the production of mucosal galactose-deficient IgA1 antibodies implicated in the pathogenesis of IgAN.

The latest price of budesonide sustained-release capsules (Kinpeygo) in 2024 announced on the entire Internet

Currently, it is understood that the price of a box of 4mg*120 capsules of budesonide sustained-release capsules is about 81,650$-82,000$, which is relatively expensive and requires patients to purchase it at their own expense. Medical insurance reimbursement is temporarily unavailable. The above prices are for reference only. The price of budesonide sustained-release capsules may change due to drug version, purchase channel and other factors. The actual price at the time of purchase needs to prevail. Patients are recommended to pay attention to the latest official price information or consult hospitals and medical institutions to obtain accurate prices.

The reasons why budesonide sustained-release capsules are expensive

The reasons why budesonide sustained-release capsules are expensive may include the following points.

1. Innovative patented technology: Budesonide sustained-release capsules adopt TARGITTM patented technology. This dual innovative process and patented technology of targeting and sustained-release increases R&D and production costs.

2. Research and development costs: The research and development of new drugs requires a large amount of capital investment, including clinical trials, drug testing and regulatory approval. These high research and development costs are often reflected in drug pricing.

3. Production cost: The production of budesonide sustained-release capsules may involve complex processes and high-quality raw materials, which may lead to higher production costs.

Manifestations of overdose of budesonide extended-release capsules

Acute toxicity caused by overdose of budesonide extended-release capsules is much less common than acute toxicity caused by overdose of long-term treatment of budesonide extended-release capsules, but both may lead to systemic toxicity manifested as hypercortisolism. Symptoms of overdose include darkening and thinning of the skin, changes in body fat around the face, neck, back and waist, acne or increased facial hair, menstrual problems, and less specific symptoms such as diarrhea, dizziness, loss of appetite, depression, nausea, rash, unusual tiredness or weakness, or vomiting.

In addition, excessive use of budesonide sustained-release capsules may reduce the body's ability to fight infections, which may lead to repeated or persistent infections, such as pneumonia, urinary tract infections, etc.

In the event of overdose of budesonide extended-release capsules, you should seek medical attention immediately and receive appropriate treatment under the guidance of a doctor.